Vectorite Biomedical (ROCO:4170) Total Assets: NT$509.56 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4170 Vectorite Biomedical Inc ROCO:4170
69 GF Score
Price NT$12.60
GF Value NT$17.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vectorite Biomedical Total Assets?

Vectorite Biomedical ROCO:4170 +0.80% 69 Total Assets is NT$509.56 Mil as of Dec. 2025. GuruFocus rates ROCO:4170 with a GF Score™ of 69/100 and a GF Value™ of NT$17.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Vectorite Biomedical's Total Assets for the quarter that ended in Dec. 2025 was NT$509.56 Mil.

During the past 12 months, Vectorite Biomedical's average Total Assets Growth Rate was 48.70% per year. During the past 3 years, the average Total Assets Growth Rate was 10.30% per year. During the past 5 years, the average Total Assets Growth Rate was 1.80% per year. During the past 10 years, the average Total Assets Growth Rate was -2.80% per year.

During the past 13 years, Vectorite Biomedical's highest 3-Year average Total Assets Growth Rate was 109.90%. The lowest was -12.90%. And the median was -3.20%.

Total Assets is connected with ROA %. Vectorite Biomedical's annualized ROA % for the quarter that ended in Dec. 2025 was 39.86%. Total Assets is also linked to Revenue through Asset Turnover. Vectorite Biomedical's Asset Turnover for the quarter that ended in Dec. 2025 was 0.06.

Vectorite Biomedical  (ROCO:4170) Total Assets Explanation

Total Assets is connected with ROA %.

Vectorite Biomedical's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=184.698/( (417.083+509.558)/ 2 )
=184.698/463.3205
=39.86 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Vectorite Biomedical's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=27.676/( (417.083+509.558)/ 2 )
=27.676/463.3205
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Vectorite Biomedical Total Assets Related Terms

Vectorite Biomedical Total Assets Historical Data

* Premium members only.

The historical data trend for Vectorite Biomedical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectorite Biomedical Total Assets Chart

Vectorite Biomedical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 492.65 465.82 452.10 412.78 509.56

Vectorite Biomedical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 452.10 438.24 412.78 417.08 509.56
ROCO:4170
69GF Score
Vectorite Biomedical Inc ROCO:4170
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectorite Biomedical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Vectorite Biomedical's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=485.076+24.482
=509.56

Vectorite Biomedical's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=485.076+24.482
=509.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of NT$509.56 Mil mean?
Vectorite Biomedical (ROCO:4170) has a Total Assets of NT$509.56 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Vectorite Biomedical and its competitors.
Is Vectorite Biomedical's Total Assets too high?
Vectorite Biomedical's current Total Assets is NT$509.56 Mil. Overall, Vectorite Biomedical has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Total Assets compare to VRTX and REGN?
Vectorite Biomedical's Total Assets of NT$509.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Vectorite Biomedical and its competitors. Vectorite Biomedical's current Total Assets is NT$509.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.58, compared to a current price of NT$12.60 — trading 28.3% below its estimated fair value. The current Total Assets is NT$509.56 Mil. Vectorite Biomedical's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Total Assets is NT$509.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?

Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued. The current stock price of NT$12.60 is trading 28.3% below its estimated GF Value™ of NT$17.58. GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.

Key valuation signals for ROCO:4170:

  • Total Assets: NT$509.56 Mil
  • GF Value™: NT$17.58 vs. price of NT$12.60 (28.3% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vectorite Biomedical Business Description

Address Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
69GF Score

Get the complete analysis for ROCO:4170

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.60
Price
NT$17.58
GF Value